Baird lowered the firm’s price target on Leap Therapeutics to $9 from $11 and keeps an Outperform rating on the shares. The firm said 4Q23 earnings update was straightforward ahead of readouts from two large randomized, controlled Phase 2 clinical trials of lead agent DKN-01 for cancer and Baird continues to view the data to date for DKN-01 in gastric cancer as underappreciated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LPTX:
